Want to see HK:2268 full AI Analyst Report?
2268 Stock Chart & Stats
HK$54.80
HK$1.55(5.24%)
At close: 4:00 PM EST
HK$54.80
HK$1.55(5.24%)
Day’s Range― - ―
52-Week RangeHK$43.50 - HK$85.50
Previous CloseN/A
Volume4.11M
Average Volume (3M)6.66M
Market Cap
HK$72.51B
Enterprise ValueHK$49.23B
Total Cash (Recent Filing)HK$7.47B
Total Debt (Recent Filing)HK$879.52M
Price to Earnings (P/E)42.1
Beta1.02
Next Earnings
Aug 24, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding1,262,105,200
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$81.36Price Target Upside48.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.54
Revenue Forecast (FY)HK$8.05B
Bulls Say, Bears Say
Bulls Say
Specialized ADC CDMO FranchiseA focused ADC CDMO model creates durable competitive advantages: technical know-how across ADC discovery, analytical, and GMP manufacturing raises switching costs, fosters long-term partnerships, and aligns with structural outsourcing by biopharma for complex modalities.
Sustained Revenue GrowthMulti-year top-line expansion demonstrates growing market share in a high-growth niche. Consistent revenue gains support capacity utilization and justify capex for scale, underpinning predictable service pipeline and recurring contract revenue over the medium term.
High Operating And Net MarginsElevated margins indicate strong pricing power and operational efficiency in complex ADC services. Durable profitability provides internal funds for reinvestment, supports attractive returns on equity, and cushions the business through cyclical demand variations.
Bears Say
Volatile Free Cash Flow / Weak Cash ConversionInconsistent conversion of earnings into free cash reduces financial flexibility for sustained capex, debt paydown, or shareholder returns. Volatility suggests timing of working capital and reinvestment needs can materially alter available cash and funding plans over the medium term.
Margin Compression Risk As Business ScalesObserved margin compression signals rising cost intensity—from scaling GMP operations, higher input or labor costs, or mix shift to earlier-stage work. If persistent, this reduces the structural profitability cushion and pressures return metrics despite revenue growth.
Concentration Risk In ADC SpecializationHeavy focus on ADCs concentrates revenue exposure to one modality and its development cycles. Adverse shifts in ADC demand, client program delays, or customer vertical integration could materially impact bookings and capacity utilization over several quarters to years.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$43.50 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$72.51B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Aug 24, 2026 which is in 39 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Mar 23, 2026. The company reported HK$0.706 earnings per share for the quarter, missing the consensus estimate of HK$0.717 by -HK$0.012.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.9.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,262,105,200 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.706 in its last earnings report, missing expectations of HK$0.717. Following the earnings report the stock price went down -4.06%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$81.36 (48.46% Upside)
HK$81.36 (48.46% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.79%
12-Months-Change
Fundamentals
Return on Equity
16.29%
Trailing 12-Months
Asset Growth
65.58%
Trailing 12-Months
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$81.36
▲(48.46% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―